Journal Article
. 2017 Jul;2().
doi: 10.1038/npjbcancer.2016.17.

Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study

Valentina I Petkov 1 Dave P Miller 2 Nadia Howlader 1 Nathan Gliner 2 Will Howe 3 Nicola Schussler 3 Kathleen Cronin 1 Frederick L Baehner 2 Rosemary Cress 4 Dennis Deapen 5 Sally L Glaser 6 Brenda Y Hernandez 7 Charles F Lynch 8 Lloyd Mueller 9 Ann G Schwartz 10 Stephen M Schwartz 11 Antoinette Stroup 12 Carol Sweeney 13 Thomas C Tucker 14 Kevin C Ward 15 Charles Wiggins 16 Xiao-Cheng Wu 17 Lynne Penberthy 1 Steven Shak 2 
Affiliations
  • PMID: 28721379
  •     27 References
  •     48 citations

Abstract

The 21-gene Recurrence Score assay is validated to predict recurrence risk and chemotherapy benefit in hormone-receptor-positive (HR+) invasive breast cancer. To determine prospective breast-cancer-specific mortality (BCSM) outcomes by baseline Recurrence Score results and clinical covariates, the National Cancer Institute collaborated with Genomic Health and 14 population-based registries in the the Surveillance, Epidemiology, and End Results (SEER) Program to electronically supplement cancer surveillance data with Recurrence Score results. The prespecified primary analysis cohort was 40-84 years of age, and had node-negative, HR+, HER2-negative, nonmetastatic disease diagnosed between January 2004 and December 2011 in the entire SEER population, and Recurrence Score results (N=38,568). Unadjusted 5-year BCSM were 0.4% (n=21,023; 95% confidence interval (CI), 0.3-0.6%), 1.4% (n=14,494; 95% CI, 1.1-1.7%), and 4.4% (n=3,051; 95% CI, 3.4-5.6%) for Recurrence Score <18, 18-30, and ⩾31 groups, respectively (P<0.001). In multivariable analysis adjusted for age, tumor size, grade, and race, the Recurrence Score result predicted BCSM (P<0.001). Among patients with node-positive disease (micrometastases and up to three positive nodes; N=4,691), 5-year BCSM (unadjusted) was 1.0% (n=2,694; 95% CI, 0.5-2.0%), 2.3% (n=1,669; 95% CI, 1.3-4.1%), and 14.3% (n=328; 95% CI, 8.4-23.8%) for Recurrence Score <18, 18-30, ⩾31 groups, respectively (P<0.001). Five-year BCSM by Recurrence Score group are reported for important patient subgroups, including age, race, tumor size, grade, and socioeconomic status. This SEER study represents the largest report of prospective BCSM outcomes based on Recurrence Score results for patients with HR+, HER2-negative, node-negative, or node-positive breast cancer, including subgroups often under-represented in clinical trials.

The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort.
Foluso O Ademuyiwa, Austin Miller, +5 authors, Sunil Badve.
Breast Cancer Res Treat, 2011 Jan 05; 126(3). PMID: 21197567
Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older.
R Yancik, M N Wesley, +3 authors, J W Yates.
JAMA, 2001 Mar 17; 285(7). PMID: 11180731
Highly Cited.
The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.
Jennifer E Joh, Nicole N Esposito, +10 authors, Geza Acs.
Oncologist, 2011 Oct 22; 16(11). PMID: 22016474    Free PMC article.
GRACE principles: recognizing high-quality observational studies of comparative effectiveness.
Nancy A Dreyer, Sebastian Schneeweiss, +5 authors, GRACE Initiative.
Am J Manag Care, 2010 Jun 22; 16(6). PMID: 20560690
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.
Laurel A Habel, Steven Shak, +12 authors, Charles P Quesenberry.
Breast Cancer Res, 2006 Jun 02; 8(3). PMID: 16737553    Free PMC article.
Highly Cited.
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Mitch Dowsett, Jack Cuzick, +11 authors, Steven Shak.
J Clin Oncol, 2010 Mar 10; 28(11). PMID: 20212256
Highly Cited.
Age-Related Disparity in Immediate Prognosis of Patients with Triple-Negative Breast Cancer: A Population-Based Study from SEER Cancer Registries.
Wenjie Zhu, Edith A Perez, +2 authors, Binghe Xu.
PLoS One, 2015 May 29; 10(5). PMID: 26020519    Free PMC article.
Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection.
Shelly S Lo, Patricia B Mumby, +8 authors, Kathy S Albain.
J Clin Oncol, 2010 Jan 13; 28(10). PMID: 20065191
Highly Cited.
Variation in 'standard care' for breast cancer across Europe: a EUROCARE-3 high resolution study.
Claudia Allemani, Hans Storm, +24 authors, Milena Sant.
Eur J Cancer, 2010 Mar 20; 46(9). PMID: 20299206
Different patterns in the prognostic value of age for breast cancer-specific mortality depending on hormone receptor status: a SEER population-based analysis.
Yi-Rong Liu, Yi-Zhou Jiang, Ke-Da Yu, Zhi-Ming Shao.
Ann Surg Oncol, 2014 Sep 25; 22(4). PMID: 25249260
Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.
Frederick L Baehner, Ninah Achacoso, +5 authors, Laurel A Habel.
J Clin Oncol, 2010 Aug 11; 28(28). PMID: 20697093
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Comparison of SEER Treatment Data With Medicare Claims.
Anne-Michelle Noone, Jennifer L Lund, +4 authors, Joan L Warren.
Med Care, 2014 Mar 19; 54(9). PMID: 24638121    Free PMC article.
Highly Cited.
Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer.
Ruth Oratz, Dev Paul, Allen L Cohn, Scot M Sedlacek.
J Oncol Pract, 2007 Jul 01; 3(4). PMID: 20859407    Free PMC article.
Improved estimates of cancer-specific survival rates from population-based data.
Nadia Howlader, Lynn A G Ries, +3 authors, Kathleen A Cronin.
J Natl Cancer Inst, 2010 Oct 13; 102(20). PMID: 20937991    Free PMC article.
Highly Cited.
Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer.
Willemien van de Water, Christos Markopoulos, +12 authors, Stephen E Jones.
JAMA, 2012 Feb 10; 307(6). PMID: 22318280
Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities.
Carol E DeSantis, Rebecca L Siegel, +4 authors, Ahmedin Jemal.
CA Cancer J Clin, 2016 Feb 26; 66(4). PMID: 26910411
Highly Cited.
Using a composite index of socioeconomic status to investigate health disparities while protecting the confidentiality of cancer registry data.
Mandi Yu, Zaria Tatalovich, James T Gibson, Kathleen A Cronin.
Cancer Causes Control, 2013 Nov 02; 25(1). PMID: 24178398
Breast cancer treatment guidelines in older women.
Sharon H Giordano, Gabriel N Hortobagyi, +2 authors, Melissa L Bondy.
J Clin Oncol, 2005 Feb 01; 23(4). PMID: 15681522
West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.
Oleg Gluz, Ulrike A Nitz, +18 authors, Nadia Harbeck.
J Clin Oncol, 2016 Mar 02; 34(20). PMID: 26926676
Highly Cited.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Disparities in breast cancer characteristics and outcomes by race/ethnicity.
Siew Loon Ooi, Maria Elena Martinez, Christopher I Li.
Breast Cancer Res Treat, 2010 Nov 16; 127(3). PMID: 21076864    Free PMC article.
Highly Cited.
American society of clinical oncology policy statement: disparities in cancer care.
Elizabeth Goss, Ana Maria Lopez, +3 authors, Derek Raghavan.
J Clin Oncol, 2009 May 01; 27(17). PMID: 19403885
Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status.
Lisa A Newman, Kent A Griffith, +3 authors, Graham A Colditz.
J Clin Oncol, 2006 Mar 22; 24(9). PMID: 16549828
Highly Cited.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +28 authors, George W Sledge.
N Engl J Med, 2015 Sep 29; 373(21). PMID: 26412349    Free PMC article.
Highly Cited.
Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
Carlos H Barcenas, Akshara Raghavendra, +10 authors, Debu Tripathy.
Cancer, 2017 Feb 16; 123(13). PMID: 28199747    Free PMC article.
The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.
Gulisa Turashvili, Edi Brogi, +4 authors, Hannah Y Wen.
Breast Cancer Res Treat, 2017 Jun 04; 165(1). PMID: 28577081    Free PMC article.
Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry.
Salomon M Stemmer, Mariana Steiner, +13 authors, Noa Ben-Baruch.
NPJ Breast Cancer, 2017 Sep 14; 3. PMID: 28900632    Free PMC article.
Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry.
Salomon M Stemmer, Mariana Steiner, +21 authors, Nicky Liebermann.
NPJ Breast Cancer, 2017 Sep 14; 3. PMID: 28900633    Free PMC article.
Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2- node positive breast cancer-A National Cancer Database study.
Prema P Peethambaram, Tanya L Hoskin, +3 authors, Judy C Boughey.
NPJ Breast Cancer, 2017 Oct 27; 3. PMID: 29067357    Free PMC article.
First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer.
Maria Vittoria Dieci, Valentina Guarneri, +15 authors, PierFranco Conte.
Oncologist, 2017 Nov 15; 23(3). PMID: 29133514    Free PMC article.
Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer.
Anna Weiss, Mariana Chavez-MacGregor, +6 authors, Elizabeth A Mittendorf.
JAMA Oncol, 2017 Dec 10; 4(2). PMID: 29222540    Free PMC article.
Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada.
Sofia Torres, Maureen Trudeau, +7 authors, Andrea Eisen.
Oncologist, 2018 Jan 27; 23(7). PMID: 29371476    Free PMC article.
Molecular Characterization and Mortality From Breast Cancer in Men.
Suleiman Alfred Massarweh, George W Sledge, +3 authors, Steven Shak.
J Clin Oncol, 2018 Mar 28; 36(14). PMID: 29584547    Free PMC article.
The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
Frédérique Penault-Llorca, Thomas Filleron, +12 authors, Henri Roché.
BMC Cancer, 2018 May 08; 18(1). PMID: 29728098    Free PMC article.
Prognostic gene expression assays in breast cancer: are two better than one?
Joseph A Sparano.
NPJ Breast Cancer, 2018 May 31; 4. PMID: 29845110    Free PMC article.
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2018 Jun 05; 379(2). PMID: 29860917    Free PMC article.
Highly Cited.
Clinical application and utility of genomic assays in early-stage breast cancer: key lessons learned to date.
S K L Chia.
Curr Oncol, 2018 Jun 19; 25(Suppl 1). PMID: 29910655    Free PMC article.
Review.
Lymph Node Status in Breast Cancer Does Not Predict Tumor Biology.
Danielle M Bello, Christy Russell, +2 authors, Monica Morrow.
Ann Surg Oncol, 2018 Jul 04; 25(10). PMID: 29968028    Free PMC article.
Adherence to guidelines in requesting Oncotype DX in a publicly funded health care system.
S Martel, M Lambertini, +2 authors, C Prady.
Curr Oncol, 2018 Aug 17; 25(4). PMID: 30111977    Free PMC article.
Clinical relevance of the 21-gene Recurrence Score® assay in treatment decisions for patients with node-positive breast cancer in the genomic era.
Eleftherios P Mamounas, Christy A Russell, +2 authors, Kathy S Albain.
NPJ Breast Cancer, 2018 Aug 30; 4. PMID: 30155517    Free PMC article.
Review.
Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
Maria Vittoria Dieci, Valentina Guarneri, +16 authors, Veneto Oncology Network.
Oncologist, 2019 Jun 04; 24(11). PMID: 31152079    Free PMC article.
The effect of Oncotype DX® on adjuvant chemotherapy treatment decisions in early breast cancer.
M A Rabie, A Rankin, A Burger, Mmg Youssef.
Ann R Coll Surg Engl, 2019 Jun 21; 101(8). PMID: 31219316    Free PMC article.
Multigene expression signatures in early hormone receptor positive HER 2 negative breast cancer.
Tanja Ovcaricek, Iztok Takac, Erika Matos.
Radiol Oncol, 2019 Sep 26; 53(3). PMID: 31553709    Free PMC article.
Review.
Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia.
Lindsay J Collin, Ming Yan, +8 authors, Lauren E McCullough.
NPJ Breast Cancer, 2019 Oct 05; 5. PMID: 31583272    Free PMC article.
Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26-30.
Seho Park, Yunan Han, +7 authors, Yikyung Park.
Breast Cancer Res, 2019 Oct 18; 21(1). PMID: 31619259    Free PMC article.
Cost-utility analysis of 21-gene assay for node-positive early breast cancer.
L Masucci, S Torres, +5 authors, W Isaranuwatchai.
Curr Oncol, 2019 Nov 12; 26(5). PMID: 31708649    Free PMC article.
Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial.
Angela Mariotto, Jinani Jayasekerea, +5 authors, Jeanne S Mandelblatt.
J Natl Cancer Inst, 2019 Jun 06; 112(2). PMID: 31165854    Free PMC article.
Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer.
Jinani Jayasekera, Yisheng Li, +21 authors, CISNET-BOLD Collaborative Group.
J Natl Cancer Inst, 2018 May 03; 110(12). PMID: 29718314    Free PMC article.
Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer.
Jinani Jayasekera, Clyde B Schechter, +17 authors, CISNET-BOLD Collaborative Group.
J Natl Cancer Inst, 2018 Sep 22; 110(12). PMID: 30239794    Free PMC article.
Introduction of a New Staging System of Breast Cancer for Radiologists: An Emphasis on the Prognostic Stage.
Jieun Koh, Min Jung Kim.
Korean J Radiol, 2019 Jan 11; 20(1). PMID: 30627023    Free PMC article.
Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
A Matikas, T Foukakis, S Swain, J Bergh.
Ann Oncol, 2019 May 28; 30(7). PMID: 31131397    Free PMC article.
Review.
Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays.
David M Hyams, Eric Schuur, +7 authors, Aníbal Nuñez De Pierro.
J Surg Oncol, 2017 Feb 18; 115(6). PMID: 28211064    Free PMC article.
Review.
Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
Ontario Health (Quality).
Ont Health Technol Assess Ser, 2020 Apr 15; 20(10). PMID: 32284770    Free PMC article.
Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer.
Jinani Jayasekera, Joseph A Sparano, +5 authors, Jeanne Mandelblatt.
JNCI Cancer Spectr, 2020 Apr 28; 3(4). PMID: 32337487    Free PMC article.
Distribution of the 21-Gene Breast Recurrence Score in Patients with Primary Breast Cancer in Germany.
Vincent P Walter, Florin-Andrei Taran, +6 authors, Andreas Daniel Hartkopf.
Geburtshilfe Frauenheilkd, 2020 Jun 23; 80(6). PMID: 32565552    Free PMC article.
Simulation of Chemotherapy Effects in Older Breast Cancer Patients With High Recurrence Scores.
Young Chandler, Jinani C Jayasekera, +3 authors, Jeanne S Mandelblatt.
J Natl Cancer Inst, 2019 Oct 16; 112(6). PMID: 31612208    Free PMC article.
Adjuvant Chemotherapy for Older Patients With Breast Cancer: When Is the Pain Worth the Gain?
Rachel A Freedman, Eric P Winer.
J Natl Cancer Inst, 2019 Oct 16; 112(6). PMID: 31612212    Free PMC article.
Mucinous Histology Might Be an Indicator for Enhanced Survival Benefit of Chemotherapy in Stage II Colon Cancer.
Yong Huang, Kuanxue Ge, +2 authors, Wei Wei.
Front Med (Lausanne), 2020 Jun 26; 7. PMID: 32582726    Free PMC article.
Nodal positivity decreases with age in women with early-stage, hormone receptor-positive breast cancer.
Stephanie M Downs-Canner, Charles E Gaber, +4 authors, David W Ollila.
Cancer, 2019 Dec 21; 126(6). PMID: 31860136    Free PMC article.
Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26-30.
Jing Yu, Jiayi Wu, +6 authors, Kunwei Shen.
Oncol Lett, 2020 Jul 30; 20(2). PMID: 32724396    Free PMC article.
The healthcare value of the Magee Decision Algorithm™: use of Magee Equations™ and mitosis score to safely forgo molecular testing in breast cancer.
Rohit Bhargava, Beth Z Clark, +2 authors, David J Dabbs.
Mod Pathol, 2020 Mar 24; 33(8). PMID: 32203092    Free PMC article.
The 21-Gene Recurrence Score Assay and Prediction of Chemotherapy Benefit: A Propensity Score-Matched Analysis of the SEER Database.
In Sil Choi, Jiwoong Jung, +5 authors, Ki-Tae Hwang.
Cancers (Basel), 2020 Jul 12; 12(7). PMID: 32650374    Free PMC article.
The Distribution and Outcomes of the 21-Gene Recurrence Score in T1-T2N0 Estrogen Receptor-Positive Breast Cancer With Different Histologic Subtypes.
Jun Wang, Zhen-Yu He, +3 authors, San-Gang Wu.
Front Genet, 2019 Jan 09; 9. PMID: 30619463    Free PMC article.
Gene Expression Assays for Early-Stage Hormone Receptor-Positive Breast Cancer: Understanding the Differences.
Ana Tablante Nunes, Deborah E Collyar, Lyndsay N Harris.
JNCI Cancer Spectr, 2017 Dec 11; 1(1). PMID: 31360834    Free PMC article.
Review.
Molecular characterization of breast cancer needle core biopsy specimens by the 21-gene Breast Recurrence Score test.
Debbie M Jakubowski, Helen Bailey, +7 authors, Frederick L Baehner.
J Surg Oncol, 2020 Jun 05;. PMID: 32497318    Free PMC article.
Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancer.
Yunan Han, Zhi-Feng Miao, +3 authors, Ying Liu.
Breast Cancer Res Treat, 2020 Sep 16; 184(3). PMID: 32929567    Free PMC article.
Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
Hannah Y Wen, Melissa Krystel-Whittemore, +7 authors, Edi Brogi.
Cancer, 2016 Aug 16; 123(1). PMID: 27526056    Free PMC article.
Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial.
Harry D Bear, Wen Wan, +8 authors, Amy P Sing.
J Surg Oncol, 2017 Apr 14; 115(8). PMID: 28407247    Free PMC article.
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Ulrike Nitz, Oleg Gluz, +18 authors, Nadia Harbeck.
Breast Cancer Res Treat, 2017 Jul 01; 165(3). PMID: 28664507    Free PMC article.
Analysis of the Trends in Publications on Clinical Cancer Research in Mainland China from the Surveillance, Epidemiology, and End Results (SEER) Database: Bibliometric Study.
Min-Qiang Lin, Chen-Lu Lian, +5 authors, San-Gang Wu.
JMIR Med Inform, 2020 Nov 18; 8(11). PMID: 33200992    Free PMC article.
Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center.
Katya Losk, Rachel A Freedman, +7 authors, Tari A King.
Breast Cancer Res Treat, 2020 Sep 18; 185(1). PMID: 32939592
Association of Race/Ethnicity and the 21-Gene Recurrence Score With Breast Cancer-Specific Mortality Among US Women.
Kent F Hoskins, Oana C Danciu, Naomi Y Ko, Gregory S Calip.
JAMA Oncol, 2021 Jan 22;. PMID: 33475714    Free PMC article.